Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome Mounjaro users notice that their KwikPen appears to contain slightly more liquid than the four doses it is designed to deliver. Whether that remainder can or should be used as an extra dose is a question our prescribers hear regularly. The short answer is no: each pen is calibrated and licensed to deliver exactly four weekly doses at a fixed volume, and attempting to extract more is not safe, not recommended by Eli Lilly or the MHRA, and not supported by the Mounjaro SmPC on the eMC. These are Prescription-Only Medicines; every aspect of how they are used, including when and how much, is a clinical decision made between you and your prescriber.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen is an engineered, single-use device. Press the button, and an internal plunger moves a fixed distance, pushing exactly the right volume of solution through the needle. That process happens four times across the pen's life. After the fourth dose, a mechanical lock engages, the button physically cannot be pressed again. This is not a coincidence or a flaw. It is a deliberate design feature to prevent accidental use beyond the intended four doses.
What many people notice is that, even after the lock engages, you can see or feel liquid still in the cartridge. That residual volume is intentional. Pharmaceutical pens for injectable medicines are manufactured with what is called overfill: extra solution included to account for priming the device, any air in the delivery path, and the dead space in the needle tip. The overfill is there to guarantee four accurate doses are delivered, not to provide a fifth one.
The volume of that overfill is not designed, calibrated, or tested as a therapeutic dose. If you could somehow access it, you would have no way of knowing how much tirzepatide it contained, whether the concentration was consistent, or whether the solution had been compromised by repeated handling of the pen. That uncertainty matters for a medicine where dosing precision directly affects tolerability and efficacy. For more background on how the pen works dose by dose, see our Mounjaro overview page.
To access the residual liquid, a person would need to remove the needle after use, reattach a fresh needle, and attempt to depress the plunger or aspirate the contents, after the lock has already engaged. Some people describe forcing the mechanism or using a syringe to draw liquid out through the needle port. Every one of these approaches carries real risk.
First, the lock exists partly as a safety control: defeating it means operating the device outside its tested parameters. Second, a used pen has already had a needle attached and removed; any subsequent manipulation introduces contamination risk. Third, and most practically, you cannot know what dose you are taking. If you are curious about whether it is possible to get an extra dose out of Mounjaro, the honest answer is that the residual volume might be 0.02ml or it might be more, and tirzepatide is a highly active medicine where the gap between a sub-therapeutic amount and an amount that causes significant nausea, vomiting or worse is not something to experiment with outside clinical supervision.
The NHS medicines page for tirzepatide is clear that the pen should be used as directed and disposed of after the four doses. If you have questions about what you noticed in your pen, the right person to ask is your prescriber, not a forum. A note on disposal: a sharps container is the correct way to discard used pens.
Occasionally a user feels uncertain whether a dose actually delivered, the pen clicked, but was the needle in position? Did anything go wrong? This is different from trying to extract extra liquid, and it deserves a different answer. If you genuinely cannot confirm that a dose delivered correctly, contact your prescriber the same day rather than attempting a second press or switching to a new pen on your own judgment. Your prescriber can advise whether to proceed that week or wait until your next scheduled dose day.
If you miss a dose entirely and your next scheduled dose is more than four days away, the general guidance is that the missed dose can be taken. If your next dose is within four days, you skip the missed one and continue on your usual day. But missed-dose decisions should always go back to the Patient Information Leaflet and your own prescriber. The titration schedule (which moves from the 2.5mg starter pen through higher strengths) exists to let your body adjust; trying to compensate for a missed dose by using leftover liquid from a finished pen is not the answer. You can find more detail on the starter dose rationale on the Mounjaro 5mg pen page.
Practically speaking, keeping your pen stored correctly makes accidental loss of a dose less likely. Mounjaro pens are refrigerated between 2°C and 8°C. Many people find the fridge door shelf (next to the butter, in plain sight) is the easiest place to remember them. Once you've taken a pen out for a dose, refer to the Patient Information Leaflet for guidance on how long it can stay at room temperature.
None of this is cause for alarm. The vast majority of people who ask about residual liquid are asking in good faith, they want to get the most from their treatment, and noticing leftover solution feels like waste. That instinct is understandable. We explain in detail what getting the golden dose out of Mounjaro actually means, and the answer is simply that the pen's design means the residual is not a usable dose; the four injections you received were complete and accurate.
Where a prescriber's input genuinely helps is in any situation where you feel your treatment is not working as expected, or you are wondering whether your current dose level is right for you. Those are clinical questions. If you want a fuller picture of what people mean when they talk about getting the golden dose from a Mounjaro pen, titration decisions (when to move from one strength to the next) are always made in consultation with your prescriber based on your response and tolerability, not by extending pens. Our clinical team at nume reviews each repeat order individually before anything is dispensed; that review is where dose questions belong.
If cost is part of what is driving this question, it is worth knowing that the price of private treatment varies considerably, and what you pay should always include clinical support, not just the pen itself. Our guide to Mounjaro pricing in the UK covers what the market looks like honestly, including what to expect from providers at different price points. For anyone ready to talk through their treatment, you can speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.